HMP Market Access Insights

Big news in the biosimilars world...the FDA's recent guidance on interchangeability is making waves! The American College of Rheumatology (ACR) applauds the FDA's move to streamline approvals, but they're also calling for caution and transparency in pharmacy-level substitutions. Meanwhile, Congress is pushing the Increasing Access to Biosimilars Act of 2023, which could incentivize providers to prescribe biosimilars through shared savings. What does this mean for health care? Potentially lower prices, better access, and a shakeup in the biologics market. But questions remain: - Will we see a surge in interchangeable biosimilars? - How will this affect drug pricing and patient access? - How will stakeholders adapt? The biosimilars landscape is changing fast. Are you ready for the impact? #BehindtheBill #HMPMarketAccessInsights #Biosimilars #HealthcareInnovation #FDA #Pharma #Biologics #DrugPricing #HealthcarePolicy #PatientAccess #MedicalResearch #Pharmacy

Rapid advancements in bispecific antibodies (BsAbs) are transforming the treatment landscape! The past two years have seen a surge in new approvals, increasing both supply and demand. Integrated delivery network (IDN) providers now face the challenge of expanding clinic and provider capacity while managing adverse effects, operational complexities, and costs. Shifting select services to lower acuity and community settings is a potential solution. 🔗 Learn more about the latest in BsAb treatments: https://lnkd.in/e3dANx5V #Oncology #BispecificAntibodies #HealthcareInnovation #PatientCare #IntegratedDeliveryNetworks #HMPMarketAccessInsights

📊 National “vertical payers” are pushing forward with greater integration across their health plans, PBMs, and Specialty Pharmacies. Centralizing contracting operations with manufacturers is already moving forward. Stay ahead—let’s talk strategy!  https://lnkd.in/eFsYsdup #HealthcareIntegration #PayerTrends #MarketAccess #PayerInsights #Oncology #HMPMarketAccessInsights

In June, The FDA released game-changing guidance for interchangeable biosimilars, with far-reaching implications for all stakeholders. Here's what pharma manufacturers need to know: 1️⃣ Switching studies may no longer be required for interchangeability status 2️⃣ Existing analytical and clinical data can now support interchangeability claims 3️⃣ Pending biosimilar applications can be updated for interchangeability without new studies This could dramatically accelerate the path to market for interchangeable biosimilars, potentially reshaping the competitive landscape. Want the full scoop? Check out the latest Behind the Bill blog for an in-depth analysis. #BehindtheBill #HMPMarketAccessInsights #Biosimilars #PharmaNews #FDAUpdates #Interchangeability #Pharmaceuticals #DrugDevelopment #MarketAccess #HealthcareInnovation #RegulatoryAffairs

The rapid FDA approvals present both opportunities and hurdles, particularly in managing side effects and operational complexities. Manufacturers can play a vital role by offering resources like patient educational materials and reimbursement support. Let’s collaborate to navigate these challenges and expand patient access to cutting-edge treatments! Check out our recent blog post and contact us today to learn more about our Community Oncology Trend Report: https://lnkd.in/etkPFiZx #Oncology #BispecificAntibodies #CommunityOncology #HealthcareInnovation #IntegratedDeliveryNetworks #HMPMarketAccessInsights

🚀 New Report Alert! Our 2024 Payer Oncology Trend Report is here, offering crucial insights from 50 Medical and Pharmacy Directors. Discover how payer perspectives are shifting and what this means for you and your teams in 2025. Reach out to Ramon Auciello for more information! #PayerOncologyTrendReport #Oncology #PayerInsights #HealthcareTrends #HMPMarketAccessInsights 

The Strengthening Medicare and Reducing Taxpayer (SMART) Prices Act is back in the spotlight! Here's what you need to know: Key points: - Expands Medicare's drug price negotiation powers - Shortens the timeline for negotiations to just 3 years post-FDA approval - Faces fierce opposition from pharma companies Congressional outlook: Uncertain, with lawsuits pending and the 2024 elections looming. The big question: Can we balance affordable drugs with incentives for innovation? Senator Klobuchar is pushing hard for this bill. Will it reshape the future of drug pricing in America? Read our full analysis in the latest Behind the Bill blog. ⬇ #BehindTheBill #HMPMarketAccessInsights #SMARTPricesAct #MedicareReform #DrugPricing #HealthcareInnovation #PharmaDebate #CongressWatch #AffordableDrugs #HealthPolicy

🌟 Coming Soon: 2024 Payer Annual Oncology Trend Report 🌟 Unlock key insights into how payers are pursuing greater control in oncology and where they're poised to succeed. Our comprehensive research unveils the strategies of vertical, other national, and regional payers, highlighting their effectiveness and the future of cancer drug rebating. These critical insights will help you shape payer engagements, value propositions, and productive relationships. 🔍 Get Access to the Report>>https://lnkd.in/eFsYsdup #Healthcare #Oncology #MarketAccess #PayerTrends #HealthcareStrategy #HMPMarketAccessInsights

#ICYMI: Centers for Medicare & Medicaid Services recently released a game-changing IPPS rule that could reshape pharma supply chains, especially for cancer drugs. What does this mean for: 🏥 Small hospitals? 💊 Drug manufacturers? 🙍♂️ Patients needing critical medications? Our latest blog dives deep into the implications. Don't miss out on understanding this pivotal shift in healthcare resilience. Subscribe to Behind the Bill to stay ahead of the curve! #BehindtheBill #HMPMarketAccessInsights #IPPS #PharmaSupplyChain #CancerCare #HealthcarePolicy #CMS #DrugManufacturing #PatientCare #HealthcareResilience #SmallHospitals #MedicareMedicaid #HealthcareInnovation #HealthBlog

The upcoming Payer Annual Trend Report found a significant increase in vertical payer integration expected by 2026. Key areas of development include: ➡ Cancer drug coverage policy decisions ➡Manufacturer contracting for rebates and discounts ➡Internal sharing of medical and drug utilization data ➡Communications with cancer care providers Stay ahead with these transformative insights and understand how payers are gearing up for the future. 🔍 Read the full analysis here: https://lnkd.in/eUs_C2RF   #Healthcare #MarketAccess #VerticalPayers #Integration #HealthPolicy #HMPMarketAccessInsights